Publications: Dr Daire Hanna

Martín-Otal C, Hanna D, Hodivala-Dilke K, Cameron AJM, Pearce O, Propper D ( 2026 ) . Abstract 7936: Epigenetic reprogramming of stromal-epithelial crosstalk to improve immunotherapy response in pancreatic ductal adenocarcinoma . Cancer Research vol. 86 , ( 7_Supplement ) 7936 - 7936 .

Hanna D, Merrick S, Ghose A, Devlin MJ, Yang DD, Phillips E, Okines A, Chopra N et al. ( 2024 ) . Real world study of sacituzumab govitecan in metastatic triple-negative breast cancer in the United Kingdom . British Journal of Cancer vol. 130 , ( 12 ) 1916 - 1920 .

Hanna D, Chopra N ( 2022 ) . The role of PARP inhibitors in gastrointestinal cancers . Critical Reviews in Oncology/Hematology vol. 171 ,

Crolley V, Hanna D, Joharatnam-Hogan N, Chopra N, Bamac E, Desai M, Lam Y-C, Dipro S et al. ( 2021 ) . Outcomes for cancer patients on systemic anti-cancer therapies during the COVID-19 pandemic from the CAPITOL (COVID-19 Cancer PatIenT Outcomes in North London) cohort study . Journal of Clinical Oncology vol. 39 , ( 15_suppl ) 10567 - 10567 .

Crolley V, Hanna D, Joharatnam-Hogan N, Chopra N, Bamac E, Lam Y-C, Dipro S, Kanani R et al. ( 2021 ) . Outcomes for cancer patients on systemic anticancer therapies during the COVID-19 pandemic from the CAPITOL (COVID-19 Cancer PatIenT Outcomes in North London) cohort study . JOURNAL OF CLINICAL ONCOLOGY . vol. 39 ,

Lerner A, Keshwani K, Sanderson B, Board RE, Flynn M, Sharkey E, Okines A, Konstantis A et al. ( 2020 ) . Is Universal Patient Access to Fulvestrant in Hormone Receptor-positive Advanced Breast Cancer Justified? A UK Retrospective Multicentre Study . Clinical Oncology vol. 32 , ( 8 )

Keshwani K, lerner A, Sanderson B, Board RE, Flynn M, Sharkey E, Okines AFC, Konstantis A et al. ( 2019 ) . Fulvestrant in hormone receptor-positive advanced breast cancer: A UK retrospective multicenter study . Journal of Clinical Oncology . vol. 37 , e12525 - e12525 .